Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrabetadex in Niemann-Pick Type C Disease
NCT03643562Phase 3Terminated
- Sponsor
- Mandos Health
- Start
- Jun 2018
- Primary completion
- Nov 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Trappsol Cyclo in Niemann-Pick disease type C (NPC), sponsored by Mandos Health. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Jun 2018; status: terminated.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NCT03643562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643562.